| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 7 Feb 2025 | 4 Feb 2025 |
| Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve declaration of an interim dividend for the Financial Year 2024-25. Outcome of the Board Meeting (As Per Bse Announcement Dated on 07.02.2025) | ||
| Board Meeting | 4 Feb 2025 | 29 Jan 2025 |
| Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve standalone and consolidated unaudited financial results for the quarter & nine months ended 31 December 2024. Outcome of the Board Meeting held on February 04, 2025 (As Per BSE Announcement dated on 04.02.2025) | ||
| Board Meeting | 25 Oct 2024 | 22 Oct 2024 |
| Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and ha Outcome of the Board Meeting held on October 25, 2024 Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 25.10.2024) | ||
| Board Meeting | 2 Aug 2024 | 30 Jul 2024 |
| Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2024 inter alia to consider and approve The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30 2024. Outcome of the Board meeting Scheme of arrangement between Eris Oaknet Healthcare Private Limited and Eris Lifesciences Limited. (As Per BSE Announcement dated on 02.08.2024) | ||
| Board Meeting | 21 May 2024 | 14 May 2024 |
| Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 inter alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended March 31 2024. Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2024 ,inter alia, to consider and approve Update on board meeting - Fund Raising (As Per BSE Announcement Dated on 17.05.2024) Financial Results for quarter and year ended 31st March 2024 Issue of Securities Outcome of the Board Meeting (As per BSE Announcement Dated on 21/05/2024) | ||
The shares were sold at an average price of ₹1,201 each, totalling ₹1,187.41 Crore. Infinity Partners acquired these shares.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Birla Estates, Lupin, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
